Goodwin advised DeuteRx on its agreement to sell DRX-065, a novel clinical stage drug candidate, to Poxel SA for $8 million (€6.8 million). In addition, Poxel…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Ambrogio Visconti
…
This content is for Standard 1 Year members only. LoginJoin Now